News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ipsen (IPN.PA) Initiates a Phase II "Switch Maintenance" Trial in Metastatic Castrate-Resistant Prostate Cancer With Tasquinimod



10/3/2012 12:59:44 PM

PARIS & LUND, Sweden--(BUSINESS WIRE)--Regulatory News: Ipsen (Paris:IPN) (Euronext: IPN; ADR: IPSEY) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced the initiation of a new phase II proof of concept clinical trial, evaluating the activity of tasquinimod in advanced metastatic castrate resistant prostate cancer patients. The study aims at establishing the clinical efficacy of tasquinimod used as maintenance therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC) who have not progressed after a first line docetaxel based chemotherapy.

Read at BioSpace.com


comments powered by Disqus
Ipsen
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES